ConductScience.org, home

Paper39587785

Guideline for pharmacological treatment of schizophrenia 2022.

Japanese Society of Neuropsychopharmacology and 1 other. Neuropsychopharmacol Rep, 2025. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Guideline for pharmacological treatment of schizophrenia 2022. Papers, record 39587785. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39587785

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Guideline for pharmacological treatment of schizophrenia 2022.
PubMed
Journal
Neuropsychopharmacol Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
5.82, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Japanese Society of NeuropsychopharmacologyGroup
2Japanese Society of Clinical NeuropsychopharmacologyGroup

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References337

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122250585Drug-induced parkinsonism in the elderly: incidence, management and prevention.Drugs Aging2012https://conductscience.org/library/papers/22250585PubMed
215846598Electroconvulsive therapy for schizophrenia.Cochrane Database Syst Rev2005https://conductscience.org/library/papers/15846598PubMed
323602690Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.Eur Neuropsychopharmacol2013https://conductscience.org/library/papers/23602690PubMed
42863986Neuroleptic malignant syndrome.Am J Psychiatry1985https://conductscience.org/library/papers/2863986PubMed
529730938Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.Am J Psychiatry2018https://conductscience.org/library/papers/29730938PubMed
624023549Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone.Clin Psychopharmacol Neurosci2013https://conductscience.org/library/papers/24023549PubMed
715784157A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.Int J Neuropsychopharmacol2005https://conductscience.org/library/papers/15784157PubMed
823983927Clozapine-related EEG changes and seizures: dose and plasma-level relationships.Ther Adv Psychopharmacol2011https://conductscience.org/library/papers/23983927PubMed
915206667Dose response and dose equivalence of antipsychotics.J Clin Psychopharmacol2004https://conductscience.org/library/papers/15206667PubMed
1011219487Bodyweight gain with atypical antipsychotics. A comparative review.Drug Saf2001https://conductscience.org/library/papers/11219487PubMed
1120643634The assessment and treatment of water imbalance in patients with psychosis.Clin Schizophr Relat Psychoses2010https://conductscience.org/library/papers/20643634PubMed
1216172203Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med2005https://conductscience.org/library/papers/16172203PubMed
1315762814The effects of benzodiazepines on cognition.J Clin Psychiatry2005https://conductscience.org/library/papers/15762814PubMed
1432110026Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment.Neuropsychiatr Dis Treat2020https://conductscience.org/library/papers/32110026PubMed
1526651392Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study.Am J Psychiatry2016https://conductscience.org/library/papers/26651392PubMed
1612416597Clozapine-induced fevers and 1-year clozapine discontinuation rate.J Clin Psychiatry2002https://conductscience.org/library/papers/12416597PubMed
1729431197Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.Acta Psychiatr Scand2018https://conductscience.org/library/papers/29431197PubMed
189659857Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.Am J Psychiatry1998https://conductscience.org/library/papers/9659857PubMed
198515788Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.N Engl J Med1993https://conductscience.org/library/papers/8515788PubMed
2023881657Intermittent drug techniques for schizophrenia.Cochrane Database Syst Rev2013https://conductscience.org/library/papers/23881657PubMed

See all 337 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42958153
Pathways to medication adherence: a configurational analysis of psychiatric symptoms and medication attitude in patients with schizophrenia spectrum disorder receiving long-acting injectable antipsychotics.
BMC Psychiatry2026https://conductscience.org/library/papers/42958153PubMed
42952012Antipsychotic Prescriptions for Prenatal and Postpartum Women in Japan: A Large Claims Database Study.Pharmacol Res Perspect2026https://conductscience.org/library/papers/42952012PubMed
42882078Extensive Craniofacial Trauma Caused by an Intraoral Pyrotechnic Explosion in a Patient with Paranoid Schizophrenia.J Clin Med2026https://conductscience.org/library/papers/42882078PubMed
42668991Physical Therapies and Neuromodulation for Treatment-Resistant Schizophrenia: A Review of Potential Mechanisms, Efficacy, and Safety.Neuropsychiatr Dis Treat2026https://conductscience.org/library/papers/42668991PubMed
42540002Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance-pharmacodynamic analysis using VigiBase.Ther Adv Psychopharmacol2026https://conductscience.org/library/papers/42540002PubMed
42466381Nationwide expansion of the EGUIDE project in Japan: A nine-year overview.PCN Rep2026https://conductscience.org/library/papers/42466381PubMed
42309543Changes in White Blood Cell and Neutrophil Counts in Patients With Schizophrenia Treated With Lithium Carbonate, Adenine, and Ninjin-Yoei-To: A Preliminary Study.Neuropsychopharmacol Rep2026https://conductscience.org/library/papers/42309543PubMed
42230659Pharmacological treatment of schizophrenia: Japanese Expert Consensus 2025.Schizophrenia (Heidelb)2026https://conductscience.org/library/papers/42230659PubMed
42212910Clozapine-Associated Neutropenia among People on Clozapine in Japan: A Nationally Representative Retrospective Cohort Study.Schizophr Bull2026https://conductscience.org/library/papers/42212910PubMed
42117812Peripheral Transcriptomic Signatures Reveal Convergent Neuroinflammatory, Metabolic, and miRNA Dysregulation in Major Psychiatric Disorders.Biology (Basel)2026https://conductscience.org/library/papers/42117812PubMed
42102176The introduction of measurement-based care for patients with schizophrenia may improve psychiatric symptoms and guideline adherence rate.Int J Neuropsychopharmacol2026https://conductscience.org/library/papers/42102176PubMed
41929365Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a post hoc analysis of post-marketing surveillance data in Japan.Front Psychiatry2026https://conductscience.org/library/papers/41929365PubMed
41756453Distress as a bridge to suicidality in schizophrenia spectrum disorders: a network-based intervention simulation study.Res Sq2026https://conductscience.org/library/papers/41756453PubMed
41069660Factors associated with treatment failure after discharge in inpatients with schizophrenia spectrum disorders: A retrospective observational study.PCN Rep2025https://conductscience.org/library/papers/41069660PubMed
40678008Awareness and management of cognitive impairment associated with schizophrenia in psychiatrists and patients: Results from a cross-sectional survey.Schizophr Res Cogn2025https://conductscience.org/library/papers/40678008PubMed
39587785Guideline for pharmacological treatment of schizophrenia 2022.Neuropsychopharmacol Rep2025https://conductscience.org/library/papers/39587785PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39587785

GET https://conductscience.org/api/papers/v1/39587785/references?page=2